Evolution of dry powder inhaler design, formulation, and performance

Area of Science:

• Pharmaceutical Sciences
• Inhalation Drug Delivery
• Respiratory Medicine

Background:

• Growing industry focus on dry powder inhalers (DPIs) over traditional pressurized metered-dose inhalers for asthma medications.
• Effective inhaled therapy relies on optimized DPI design and powder formulation for efficient drug delivery.
• Current regulatory standards, including U.S. FDA draft guidance, emphasize consistent dose delivery across inhaler lifespan and between devices.

Purpose of the Study:

• To review the advancements in dry powder inhaler technology and formulation science.
• To address the challenges in achieving consistent dose delivery from DPIs.
• To highlight how new technologies can improve lung dose and reduce variability in inhaled therapies.

Main Methods:

• Review of recent developments in dry powder inhaler device engineering.
• Analysis of innovative powder formulation strategies to enhance drug handling and delivery.
• Examination of regulatory requirements for consistent dose emission from inhalation devices.

Main Results:

• Free micronized powder properties can negatively impact drug handling and delivery, leading to dose inconsistency.
• Formulation technologies show promise in increasing the lung dose of inhaled medications.
• Technological advancements are actively reducing the variability of delivered doses from DPIs.

Conclusions:

• While a perfect dry powder inhaler remains an aspiration, ongoing evolution in both device and formulation technology is crucial.
• These advancements are vital for overcoming the inherent challenges of powder-based inhalation systems.
• The trajectory of development aims to meet stringent regulatory demands for consistent and effective inhaled drug therapy.